Weekly Analysts’ Ratings Changes for Compass Therapeutics (CMPX)

Several brokerages have updated their recommendations and price targets on shares of Compass Therapeutics (NASDAQ: CMPX) in the last few weeks:

• 9/23/2026 – Compass Therapeutics had its “overweight” rating reaffirmed by Cantor Fitzgerald.
• 9/23/2026 – Compass Therapeutics had its price target lowered by Guggenheim to $4.00. They now have a “buy” rating on the stock.
• 9/23/2026 – Compass Therapeutics was given a new $4.00 price target by Wedbush.
• 9/23/2026 – Compass Therapeutics had its “market outperform” rating reaffirmed by Citigroup Inc..
• 9/23/2026 – Compass Therapeutics had its price target lowered by Citizens Jmp to $4.00. They now have a “market outperform” rating on the stock.
• 9/22/2026 – Compass Therapeutics was downgraded by Wedbush from “outperform” to “neutral”. They now have a $1.00 price target on the stock, down from $5.00.
• 9/22/2026 – Compass Therapeutics was downgraded by Lifesci Capital from “strong-buy” to “hold”.
• 8/8/2026 – Compass Therapeutics was downgraded by Wall Street Zen from “sell” to “strong sell”.
• 8/7/2026 – Compass Therapeutics had its price target raised by Piper Sandler from $4.00 to $6.00. They now have an “overweight” rating on the stock.

Compass Therapeutics, Inc is a clinical-stage biotechnology company focused on developing antibody-based medicines designed to activate and direct the immune system against cancer and other serious diseases. The company’s research is centered on immuno-oncology, with the goal of creating therapies that can stimulate antitumor immune responses and improve outcomes for patients.

Compass Therapeutics has developed a pipeline of proprietary antibody therapeutics, including CTX-471, an investigational monoclonal antibody intended to activate CD137, an immune-stimulatory receptor found on certain immune cells.